Table 5.

Regression models on the association between putative biomarkers and presence or absence of pain adjusting for covariates

Continuous biomarker	Coefficient	95% CI	p-value*
TGFβ1	2.28	−0.77, 5.33	0.1427
TGFβ2	14.94	−2.36, 32.24	0.0905
BDNF	−46.44	−260.58, 167.69	0.6708
GP130	4.45	0.93, 7.97	0.0131
Resistin	7.83	−2.54, 18.20	0.1388
MCP1	0.23	0.08, 0.38	0.0032
PDGFB	0.28	0.09, 0.47	0.0044
IL-6	2.08	−0.90, 5.07	0.1708
Dichotomized biomarker	Odds ratio	95% CI	p-value*
IL-4	1.09	0.93, 1.28	0.3090
SP	1.08	0.92, 1.26	0.3383

^*p-value from the regression models including covariates: etiology, pancreatitis duration, diabetes, pancreas duct stricture, gender, BMI, weight, age, prior acute pancreatitis and recurrent acute pancreatitis attacks. This analysis only includes putative biomarkers whose p-value from the regression analysis without covariate adjustment was greater than 0.2. The interpretation of the reported coefficient and odds ratio as measures of the effect size is the same as in Table 4, except that they are conditional on covariates here.